Trial Profile
A phase II study of allogeneic hematopoetic stem cell transplant for B-cell non-Hodgkin lymphoma using Zevalin, fludarabine and melphalan
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Feb 2024
Price :
$35
*
At a glance
- Drugs Fludarabine (Primary) ; Ibritumomab tiuxetan (Primary) ; Melphalan (Primary) ; Rituximab; Sirolimus; Tacrolimus; Tacrolimus
- Indications Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
- Focus Therapeutic Use
- 13 Feb 2024 Status changed from active, no longer recruiting to completed.
- 25 Oct 2023 Planned End Date changed from 30 Jun 2023 to 30 Dec 2023.
- 01 Sep 2023 Primary endpoint has been met (Relapse/Progression Rate at Two Years) , according to Results published in the Clinical Lymphoma, Myeloma & Leukemia